Having 35 copies of the CAG triplet in the gene that causes Huntington’s disease is not a problem. Inheriting 40 could be a sign that goes unnoticed for decades, until reaching 80. From there, the process accelerates and neural death occurs when reaching 150 repeats. Huntington’s disease neurodegeneration is not determined by what, but by how much, according to a study conducted at the Broad Institute. Read More
Kidney stones are largely composed of calcium oxalate (CaOx), which can cause serious renal inflammation and damage to renal tubular epithelial cells, with the CaOx crystals gradually accumulating and leading to CaOx nephrocalcinosis. Read More
Investigators at The Scripps Research Institute and Rensselaer Polytechnic Institute have designed novel covalent inhibitors of SARS-CoV-2 papain-like protease (PLpro) and assessed their drug properties in preclinical models. Read More
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) will award a seed grant of $610,000 to Justus Liebig University Giessen (JLU) to support the definition of a lead optimization path for the development of a direct-acting peptide therapeutic based on a natural-product scaffold targeting gram-negative pathogens. Read More
The membrane-associated tyrosine/threonine protein kinase 1 (PKMYT1) regulates cell cycle progression and maintains genomic integrity. If it is dysregulated, cells may enter mitosis prematurely, potentially initiating tumorigenesis. Read More
Anges Inc. has entered into a sponsored research agreement with Stanford University School of Medicine for the development of novel cancer therapies using genome editing technology. The parties aim to combine nucleic acid drug delivery technology developed at Stanford with the genome editing technology of Emendobio Inc., a subsidiary of Anges. Read More
BioWorld’s staff recaps the therapeutic trends and breakthroughs of 2024, the economic highs and lows facing the industry throughout the past year and the regulatory actions that are likely to have implications as biopharma forges ahead in 2025. Read More
BioWorld MedTech’s staff recaps the med-tech and diagnostic trends and breakthroughs of 2024, the financing trends of the past year and the regulatory actions likely to affect med-tech into 2025. Read More
Immuron Ltd. has signed a new research collaboration agreement with Monash University to develop new therapeutic drug candidates targeting antimicrobial-resistant pathogens. This work will utilize the Immuron technology platform, and the experience of the Biomedicine Discovery Institute research team. Read More
Universidade Nova De Lisboa has disclosed rhenium complexes described as potentially useful for the treatment of cancer and gram-positive bacterial infections. Read More
Augustine Therapeutics NV has synthesized new heteroaryl-amine compounds acting as histone deacetylase 6 (HDAC6) inhibitors and thus reported to be useful for the treatment of inflammation, autoimmune disease, cancer, neurodegeneration, pain, neuropathy, psychiatric and cardiovascular disorders. Read More
Corneal neovascularization (CNV) occurs when abnormal blood vessels grow into the cornea in response to ischemic or hypoxic conditions caused by infections, inflammation or chemical injuries. Read More
Jiangsu Nhwa Pharmaceutical Co. Ltd. has patented substituted imidazole derivatives acting as α2-adrenoceptor agonists with sedative and/or analgesic and/or anesthetic and/or anxiolytic activity. As such, they are reported to be potentially useful for the treatment of pain, insomnia and psychiatric disorders. Read More
It is known that mitochondrial unfolded protein response (UPRmt), initiated by the transcription factor ATF5, maintains protein homeostasis under stress conditions by folding denatured proteins, folding newly imported proteins into the mitochondria or by degrading damaged proteins. Read More
Researchers have developed an innovative immunotoxin (a fusion protein called GrB-Fc-KS49) designed to target epithelial membrane protein-2 (EMP2), a biomarker overexpressed in more than 75% of breast cancer cases, including triple-negative breast cancer (TNBC). Read More
Fox Chase Chemical Diversity Center Inc. and University of Pittsburgh have jointly described new proteolysis targeting chimeras (PROTACs) consisting of Nef (HIV-1)-targeting moiety covalently linked to cereblon (CRBN)-binding moiety. Read More
